Myth vs Fact: Blincyto Edition
Blinatumomab (Blincyto) in India Blincyto is a Bispecific T-cell engager (BiTE) immunotherapy used for the treatment of certain B-cell precursor acute lymphoblastic leukemia (ALL). Since it works differently from chemotherapy, it has led to curiosity and confusion. These confusions lead to misconceptions to patients, so here’s the article to burst the myth and present the facts. MYTH: Blincyto ( Blinatumomab ) works for all types of leukemia FACT: Blincyto is indicated in adults and children above one month old with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy. MYTH: Side-effects of Blincyto are sam...